Introduction
============

The number of heart failure (HF) patients has been rapidly increasing, such that the situation is now referred to as the 'HF pandemic'. Worldwide, approximately 26 million patients are living with HF ([@B1],[@B2]). HF will become a more serious issue in the near future with the epidemiological transition and aging of the population ([@B3]).

In this era of aging and an "HF pandemic", the population of socially vulnerable acute HF (AHF) patients (i.e., those with no partner or children or who are living alone) is expected to increase. The evaluation of the social status of each AHF patient is therefore important for preventing re-admission due to HF and a poor prognosis. Several groups have systemically investigated the impact of social determinants or isolation on the prognosis of AHF patients ([@B4]-[@B7]). Lu et al. reported that the marital status and living conditions were correlated with the mortality and readmission rate among African Americans with HF ([@B5]). Specifically, being married and living with family independently predicted a low 1-year all-cause mortality and a low 30-day readmission rate.

We also recently described the adverse prognosis of socially vulnerable AHF patients, especially those who are elderly ([@B6]). Social vulnerability has been confirmed to be an independent factor predicting the 1,000-day mortality in HF patients, and such patients have a number of factors that may lead to repeated admission and adverse outcomes after their discharge. The gender differences in characteristics among AHF patients have also been discussed in some previous reports ([@B8]-[@B10]). However, gender differences in the proportion of socially vulnerable patients and in the prognosis based on the presence of social vulnerability in AHF have not yet been reported. Such differences might be an important factor in determining the association between social factors and the HF prognosis. Investigations of the gender differences in social vulnerability might therefore help improve the social service of socially vulnerable patients.

In the present study, we newly defined socially vulnerable patients as those who met one of three criteria \[marital status (without a partner), offspring status (without children), and living status (living alone)\] and investigated the impact of gender differences on the relationship between social determinants and the long-term prognosis of AHF.

Materials and Methods
=====================

Subjects
--------

A total of 1,048 patients \[540 patients \<75 years of age (non-elderly cohort) and 508 patients ≥75 years of age (elderly cohort)\] admitted to the intensive-care unit (ICU) at Nippon Medical School Chiba Hokusoh Hospital between February 2000 and December 2014 and who had data available on social determinants were enrolled. Patients with HF caused by acute coronary syndrome were excluded from the study.

Based on the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis of AHF, we diagnosed AHF according to the plasma natriuretic peptide level \[b-type natriuretic peptide (BNP) ≥ 100 pg/mL\] (Class I, level A), a 12-lead electrocardiogram (Class I, level C), laboratory measurements (troponins, blood urea nitrogen ([@B11]), creatinine, sodium, potassium, glucose, liver function and complete blood counts) (Class I, level C) and echocardiography (Class I, level C) ([@B12]). The treating physician at the emergency department diagnosed AHF within 30 minutes of admission. AHF presented as either new-onset or decompensated chronic HF with symptoms sufficient to warrant hospitalization. The patients who met any of the following criteria were admitted to the ICU: 1) those who required high-projectile oxygen inhalation (including mechanical support) to treat orthopnea; 2) those who required inotrope or mechanical support due to low blood pressure; and 3) those who required various types of diuretics to improve general or lung edema. The treatment strategy was chosen by each physician. In all cases, diuretics or vasodilators were administered for the treatment of AHF. All of the patients had a New York Heart Association (NYHA) functional class of either III or IV.

Procedure
---------

Patients who met one of the three marital status-, offspring status-, and living status-related criteria were considered to be socially vulnerable. With regard to the marital status, patients without a partner (including those who had never been married or were divorced or widowed) were classified as socially vulnerable. With regard to the offspring status, patients who had no children were classified as socially vulnerable. With regard to the living status, patients who lived alone were classified as socially vulnerable. Patients who met at least one of these criteria were classified as socially vulnerable, and all others were classified as non-socially vulnerable.

The patients were defined as non-socially vulnerable or socially vulnerable in each cohort as follows: non-elderly male cohort \[non-socially vulnerable (n=260) and socially vulnerable (n=154)\], non-elderly female cohort \[non-socially vulnerable (n=83) and socially vulnerable (n=43)\], elderly male cohort \[non-socially vulnerable (n=193) and socially vulnerable (n=89)\], elderly female cohort \[non-socially vulnerable (n=69) and socially vulnerable (n=157)\]. We defined the elderly cohort as those ≥75 years of age, which is the population referred to as "the late elderly" in Japanese society. The Japanese Heart Failure Society provided a statement about the management of elderly HF targeting those ≥75 years of age in 2016. Furthermore, the Acute Decompensated Heart Failure Syndromes (ATTEND) registry showed that Japanese HF patients ≥75 years of age had a higher mortality rate than those \<75 years of age ([@B13]). The present study therefore focused on HF patients ≥75 years of age.

We compared the patients\' characteristics among the groups, including their age, gender, presence of *de novo* or recurrent HF, etiology of HF, risk factors for atherosclerosis (diabetes mellitus, hypertension and dyslipidemia), vital signs \[systolic blood pressure (SBP) and heart rate\], left ventricular ejection fraction (LVEF) on echocardiography, NYHA class, arterial blood gas data, laboratory data \[blood urea nitrogen ([@B11]), total bilirubin, hemoglobin, BNP, C-reactive protein (CRP) and other variables\], nutritional status \[prognostic nutritional index (PNI) and controlling nutritional status (CONUT) score\], medications administered during ICU admission and duration of admission (duration of ICU stay and hospital stay). All data were collected from the patients\' medical records.

The PNI was calculated according to the following formula: 10× serum albumin (g/dL) + 0.005× lymphocyte count (/μL) (lower = worse). The CONUT score was calculated using the serum albumin, lymphocytes and total cholesterol (range 0-12, higher = worse). In this scoring system, point values are assigned to different ranges of laboratory measurements, as follows: serum albumin ≥3.5 g/dL, 0 points; 3.49-3, 2 points; 2.99-2.5, 4 points; and \<2.5, 6 points; lymphocytes ≥1,600 μL^−1^, 0 points; 1,200-1,599, 1 point; 800-1,199, 2 points; and \<800, 3 points; and total cholesterol ≥180 mg/dL, 0 points; 140-179, 1 point; 100-139, 2 points; and \<100, 3 points. The lymphocyte count and total cholesterol were not obtained from 181 and 21 patients, respectively, so the PNI and CONUT score were calculated from the data of 869 and 867 AHF patients, respectively.

The long-term prognosis, including the 1,000-day all-cause mortality, was evaluated as the primary endpoint. The patients were routinely followed-up at an outpatient clinic. The prognoses of the patients who were followed at other institutes were determined by telephone contact. The prognostic value for 1,000-day mortality was evaluated using a Cox regression hazard model and Kaplan-Meier curves. In addition, the long-term prognosis was compared between the non-socially vulnerable and socially vulnerable groups in reduced LVEF (LVEF ≥40%, HFrEF) and preserved LVEF (LVEF \<40%, HFpEF) patients as a sub-group analysis.

Statistical analyses
--------------------

All of the statistical analyses were performed using the SPSS 22.0 software program (SPSS Japan Institute, Tokyo, Japan). All numerical data were expressed as the mean ± standard deviation or the median (25-75% interquartile range), depending on normality. If the data were normally distributed, the values were expressed as the mean ± standard deviation. If the data were not normally distributed, the values were expressed as the median (25-75% interquartile range). Normality was assessed using the Shapiro-Wilk W-test. The Mann-Whitney U-test was used for comparisons between two groups. The chi-squared test was used to compare proportions. P values of \<0.05 were considered to indicate statistical significance.

The prognostic value of social vulnerability was assessed by comparing the socially vulnerable group to the non-socially vulnerable group using a Cox regression hazard model. A Cox regression analysis was performed to determine the hazard ratio (HR) for the 1,000-day mortality. All clinically relevant factors affecting the prognosis, including the age (per 1.0-year increase), SBP (≥140 mmHg), estimated glomerular filtration rate (eGFR) (per 10-mL/min/1.73 m^2^ increase), total bilirubin (per 0.1-mg/dL), sodium (per 1.0-mmol/L increase), CRP (per 1.0-mg/dL increase), hemoglobin (per 1.0-mg/dL increase), LVEF (per 10% increase), and BNP (per 10-pg/mL increase) at admission, were included in a multivariate Cox regression hazard model to investigate factors associated with the 1,000-day all-cause mortality. A multivariate Cox regression hazard model with simultaneous forced entry was used to analyze the impact of a socially vulnerable status and all clinically relevant factors (adjusted factors). The cumulative survival rates in each of group were analyzed using Kaplan-Meier curves, and the log-rank test was used to calculate the statistical significance of the differences.

Ethics review board
-------------------

The research ethics committee of Nippon Medical School Chiba Hokusoh Hospital approved the study protocol. Regarding informed consent, we described the contents of the present study in a poster displayed at our institute, and we also shared the contents on our homepage, where it could be easily seen by anyone in accordance with the advice of the ethics committee.

Results
=======

Patient characteristics
-----------------------

The percentage of socially vulnerable patients was compared between the non-elderly cohort (n=540) and the elderly cohort (n=508); in addition, the percentage was also compared between men and women in both cohorts. The socially vulnerable patients numbered 246 (48.4%) in the elderly cohort and 197 (36.5%) in the non-elderly cohort. The proportion of socially vulnerable patients was significantly higher in the elderly cohort than in the non-elderly cohort (p\<0.001) ([Fig. 1A](#g001){ref-type="fig"}). In the non-elderly cohort, there were 154 (37.2%) socially vulnerable men and 43 (34.2%) socially vulnerable women, a non-significant difference ([Fig. 1B](#g001){ref-type="fig"}); in contrast, in the elderly cohort, there were 89 (31.5%) socially vulnerable men and 157 (69.4%) socially vulnerable women, a significant difference (p\<0.001) ([Fig. 1C](#g001){ref-type="fig"}). These results suggest that elderly female AHF patients are more likely to be socially vulnerable than elderly male AHF patients in Japanese society.

![(A) Social vulnerability was significantly more likely in the elderly cohort (n=246, 48.4%) than in the non-elderly cohort (n=197, 36.5%) (p\<0.001). (B) The rate of social vulnerability was not significantly different between the non-elderly men (n=154, 37.2%) and non-elderly women (n=43, 34.2%). (C) Social vulnerability was significantly more likely in the elderly female cohort (n=157, 69.4%) than in the elderly male cohort (n=89, 31.5%) (p\<0.001).](1349-7235-58-2931-g001){#g001}

Among male patients in the non-elderly cohort, the mean age in the socially vulnerable group was significantly younger than in the non-socially vulnerable group. Furthermore, the patients in the socially vulnerable group were less likely to have ischemic disease than those in the non-socially vulnerable group ([Table 1](#t001){ref-type="table"}). Among female patients in the non-elderly cohort, there were no significant differences in most factors ([Table 1](#t001){ref-type="table"}). However, among patients of both genders in the elderly cohort, the mean age in the socially vulnerable group was significantly older than in the non-socially vulnerable group ([Table 2](#t002){ref-type="table"}). These results suggest that aging and social vulnerability are strongly associated in both women and men with AHF.

###### 

Characteristics of the Patients in the Non-elderly Cohort.

                                   \<75 years old                                                                            
  -------------------------------- ------------------- ------------------- ------- ------------------- --------------------- -------
  Status and vital signs                                                                                                     
  Age (years old)                  66 (61-71)          62 (56-69)          0.001   66 (58-71)          69 (61-72)            0.343
  Type (readmission, %)            88 (33.8%)          51 (33.1%)          0.915   19 (22.9%)          12 (27.9%)            0.663
  LVEF (%)                         31 (22-42)          31 (23-45)          0.901   39 (30-52)          34 (26-45)            0.074
  NYHA (IV, %)                     216 (83.1%)         128 (83.1%)         1.000   58 (69.9%)          35 (81.4%)            0.202
  Systolic blood pressure (mmHg)   158 (125-186)       172 (147-199)       0.024   152 (125-179)       160 (113-180)         0.839
  Pulse (beats/min)                110 (95-131)        120 (103-138)       0.005   122 (98-140)        112 (93-128)          0.115
  Etiology                                                                                                                   
  Ischemia (yes, %)                132 (51.0%)         60 (39.0%)          0.014   23 (27.7%)          14 (32.6%)            0.680
  Past medical history                                                                                                       
  Hypertension (yes, %)            183 (70.4%)         112 (72.7%)         0.654   54 (65.1%)          26 (60.5%)            0.697
  Diabetes mellitus (yes, %)       129 (49.6%)         74 (48.1%)          0.761   39 (47.0%)          18 (41.9%)            0.706
  Dyslipidemia (yes, %)            129 (49.6%)         81 (52.6%)          0.611   41 (49.4%)          21 (48.8%)            1.000
  Arterial blood gas                                                                                                         
  pH                               7.35 (7.21-7.43)    7.33 (7.17-7.43)    0.341   7.33 (7.23-7.44)    7.34 (7.22-7.42)      0.994
  PCO~2~ (mmHg)                    40.1 (32.0-54.6)    42.2 (34.3-60.7)    0.061   44.7 (31.6-55.7)    38.6 (33.0-50.1)      0.517
  PO~2~ (mmHg)                     83.5 (65.2-124.8)   86.7 (67.1-125.8)   0.407   90.9 (65.6-114.4)   93.6 (69.3-129.5)     0.837
  HCO~3~^-^ (mmol/L)               21.5 (19.2-23.5)    22.0 (19.4-23.8)    0.200   22.3 (19.6-24.3)    21.1 (18.8-23.3)      0.222
  SaO~2~ (%)                       95 (89-98)          96 (90-98)          0.555   95 (91-98)          97 (93-98)            0.246
  Lactate (mmol/L)                 1.9 (1.3-3.7)       1.7 (1.2-3.2)       0.367   2.8 (1.2-4.5)       1.9 (1.0-3.6)         0.427
  Laboratory data                                                                                                            
  Total bilirubin (mg/dL)          0.6 (0.4-0.9)       0.6 (0.4-1.1)       0.998   0.6 (0.4-0.9)       0.5 (0.3-1.1)         0.713
  Uric acid (mg/dL)                7.0 (5.9-8.2)       7.5 (6.0-8.7)       0.060   6.6 (5.0-7.6)       6.0 (4.6-7.8)         0.498
  Sodium (mmol/L)                  140 (137-142)       140 (138-142)       0.044   139 (137-141)       139 (138-142)         0.760
  Potassium (mmol/L)               4.3 (3.9-4.8)       4.1 (3.8-4.4)       0.004   4.1 (3.8-4.5)       4.1 (3.6-4.6)         0.817
  Hemoglobin (g/dL)                13.5 (11.4-15.3)    14.2 (12.3-15.8)    0.017   12.3 (10.9-13.7)    12.3 (10.6-13.3)      0.636
  BUN (mmol/L)                     23.3 (17.7-32.8)    21.8 (16.5-32.2)    0.313   21.9 (17.3-28.9)    22.2 (16.5-30.6)      0.896
  Creatinine (g/dL)                1.27 (1.00-1.89)    1.24 (0.97-1.93)    0.449   0.93 (0.69-1.18)    1.02 (0.69-1.37)      0.353
  CRP (mg/dL)                      0.75 (0.23-2.51)    0.50 (0.21-1.62)    0.095   0.66 (0.21-2.30)    0.79 (0.15-1.87)      0.686
  BNP (pg/mL)                      685 (389-1,256)     716 (410-1,337)     0.548   571 (267-1,129)     942 (496-1,897)       0.005
  Nutritional status                                                                                                         
  PNI                              44.7 (39.8-48.3)    45.4 (40.6-49.6)    0.295   44.2 (38.8-48.9)    42.9 (39.7-48.7)      0.931
  CONUT score                      3 (1-4)             2 (1-4)             0.242   3 (1-4)             3 (1-4)               0.911
  Albumin (g/dL)                   3.7 (3.4-4.0)       3.8 (3.4-4.1)       0.508   3.8 (3.3-4.1)       3.6 (3.3-3.9)         0.348
  Lymphocyte count (/μL)           1,306 (948-1,687)   1,394 (987-1,789)   0.590   1,310 (814-1,745)   1,339 (1,025-1,687)   0.420
  Total cholesterol (mg/dL)        162 (138-187)       174 (145-203)       0.065   179 (145-222)       187 (170-204)         0.633
  Medication (cases) during ICU                                                                                              
  Furosemide (yes, %)              238 (91.5%)         141 (91.6%)         1.000   80 (96.4%)          39 (90.7%)            0.229
  Nitroglycerin (yes, %)           174 (66.9%)         111 (72.1%)         0.323   51 (61.4%)          24 (55.8%)            0.570
  Nicorandil (yes, %)              40 (15.4%)          18 (11.7%)          0.310   9 (10.8%)           7 (16.3%)             0.407
  Carperitide (yes, %)             128 (49.2%)         96 (62.3%)          0.011   40 (48.2%)          19 (44.2%)            0.710
  Dopamine (yes, %)                77 (29.6%)          39 (25.3%)          0.367   17 (20.5%)          11 (25.6%)            0.508
  Dobutamine (yes, %)              76 (29.2%)          36 (23.4%)          0.209   17 (20.5%)          7 (16.3%)             0.639
  ACE-I/ARB (yes, %)               105 (40.4%)         73 (47.4%)          0.182   41 (49.4%)          16 (37.2%)            0.257
  β-blocker (yes, %)               71 (27.3%)          45 (29.2%)          0.734   18 (21.7%)          8 (18.6%)             0.818
  Spironolactone (yes, %)          102 (39.3%)         60 (39.0%)          1.000   36 (43.4%)          20 (46.5%)            0.850
  Outcome                                                                                                                    
  ICU hospitalization (days)       5 (3-8)             5 (3-7)             0.812   5 (3-7)             4 (3-6)               0.068
  Total hospitalization (days)     28 (18-46)          27 (18-48)          0.577   27 (18-52)          28 (18-54)            0.769
  In-hospital mortality (yes, %)   28 (10.8%)          12 (7.8%)           0.391   8 (9.6%)            6 (14.0%)             0.553

LVEF: left ventricular ejection fraction measured by echocardiography, NYHA: New York Heart Association, BUN: blood urea nitrogen, CRP: C-reactive protein, BNP: brain natriuretic peptide, PNI: prognostic nutritional index, CONUT: controlling nutritional status, ACE-I: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, ICU: intensive-care unit

The p values between the non-socially vulnerable and socially vulnerable group were determined using the Mann-Whitney U-test or the χ^2^ test.

All numerical data are expressed as the median (25-75% interquartile range).

###### 

Characteristics of the Patients in the Elderly Cohort.

                                   ≥75 years old                                                                              
  -------------------------------- ------------------- ------------------- --------- ------------------- -------------------- -------
  Status and vital signs                                                                                                      
  Age (years old)                  78 (77-82)          83 (79-86)          \<0.001   81 (78-85)          84 (80-87)           0.002
  Type (re admission, %)           80 (41.5%)          39 (39.3%)          0.795     21 (30.4%)          44 (28.0%)           0.751
  LVEF (%)                         35 (28-47)          30 (23-42)          0.017     41 (33-56)          43 (30-59)           0.923
  NYHA (IV, %)                     150 (77.7%)         72 (80.9%)          0.639     55 (79.7%)          131 (83.4%)          0.571
  Systolic blood pressure (mmHg)   160 (128-180)       160 (140-180)       0.576     151 (136-180)       154 (130-180)        0.739
  Pulse (beats/min)                106 (86-123)        106 (90-126)        0.428     110 (90-121)        107 (90-128)         0.894
  Etiology                                                                                                                    
  Ischemia (yes, %)                100 (51.8%)         43 (48.3%)          0.610     24 (34.8%)          45 (28.7%)           0.433
  Past medical history                                                                                                        
  Hypertension (yes, %)            147 (76.2%)         61 (68.5%)          0.192     56 (81.2%)          125 (79.6%)          0.858
  Diabetes mellitus (yes, %)       82 (42.5%)          27 (30.3%)          0.065     27 (39.1%)          67 (42.7%)           0.662
  Dyslipidemia (yes, %)            80 (41.5%)          34 (38.2%)          0.695     32 (46.4%)          60 (38.2%)           0.304
  Arterial blood gas                                                                                                          
  pH                               7.32 (7.19-7.42)    7.32 (7.23-7.41)    0.995     7.32 (7.18-7.37)    7.34 (7.24-7.42)     0.013
  PCO~2~ (mmHg)                    43.2 (32.9-58.5)    42.0 (35.1-52.5)    0.826     48.8 (39.6-62.2)    43.8 (35.1-54.2)     0.017
  PO~2~ (mmHg)                     87.6 (65.2-133.0)   87.4 (64.3-133.0)   0.846     84.5 (70.4-141.0)   103.0 (65.5-155.0)   0.939
  HCO~3~^-^ (mmol/L)               22.2 (19.6-24.4)    22.0 (18.8-24.7)    0.519     22.2 (19.9-24.4)    22.0 (19.9-25.7)     0.651
  SaO~2~ (%)                       96 (89-98)          95 (89-98)          0.642     95 (91-98)          97 (91-98)           0.360
  Lactate (mmol/L)                 1.7 (1.1-3.2)       1.9 (1.2-3.3)       0.939     1.7 (1.3-3.2)       1.4 (1.0-2.6)        0.174
  Laboratory data                                                                                                             
  Total bilirubin (mg/dL)          0.5 (0.4-0.8)       0.6 (0.4-0.9)       0.262     0.6 (0.4-0.9)       0.5 (0.4-0.8)        0.294
  Uric acid (mg/dL)                6.4 (5.3-7.7)       7.4 (6.3-8.3)       0.003     6.3 (4.9-7.7)       5.9 (4.8-7.5)        0.664
  Sodium (mmol/L)                  139 (137-142)       140 (138-142)       0.207     141 (139-142)       140 (137-142)        0.035
  Potassium (mmol/L)               4.3 (3.9-4.8)       4.4 (3.9-4.7)       0.954     4.2 (3.8-4.6)       4.3 (3.8-4.8)        0.592
  Hemoglobin (g/dL)                12.1 (10.6-13.9)    12.1 (10.8-13.9)    0.909     11.2 (9.8-12.7)     11.1 (10.0-12.4)     0.714
  BUN (mmol/L)                     26.2 (19.2-39.1)    28.3 (19.8-43.5)    0.223     25.2 (16.6-35.7)    24.9 (18.8-34.1)     0.779
  Creatinine (g/dL)                1.40 (1.06-1.81)    1.36 (1.02-2.28)    0.689     1.04 (0.79-1.64)    1.00 (0.82-1.47)     0.700
  CRP (mg/dL)                      0.70 (0.24-2.50)    0.72 (0.18-3.04)    0.855     0.49 (0.19-1.30)    0.50 (0.14-1.89)     0.625
  BNP (pg/mL)                      736 (484-1,222)     967 (534-1,500)     0.049     1.020 (556-1,588)   870 (457-1,630)      0.634
  Nutritional status                                                                                                          
  PNI                              42.6 (38.3-47.0)    42.5 (37.7-46.8)    0.687     42.0 (38.2-44.5)    42.6 (38.0-47.8)     0.388
  CONUT score                      3 (2-5)             3 (2-5)             0.771     3 (2-5)             3 (2-5)              0.518
  Albumin (g/dL)                   3.7 (3.3-3.9)       3.6 (3.2-3.8)       0.238     3.7 (3.3-4.0)       3.7 (3.3-3.9)        0.887
  Lymphocyte count (/μL)           1,249 (929-1,529)   1,157 (831-1,591)   0.468     1,009 (804-1,352)   1,058 (703-1,504)    0.795
  Total cholesterol (mg/dL)        155 (135-182)       160 (140-180)       0.628     164 (141-191)       176 (151-206)        0.052
  Medication (cases) during ICU                                                                                               
  Furosemide (yes, %)              184 (95.3%)         87 (97.8%)          0.511     64 (92.8%)          147 (93.6%)          0.778
  Nitroglycerin (yes, %)           125 (64.8%)         58 (65.2%)          1.000     50 (72.5%)          105 (66.9%)          0.440
  Nicorandil (yes, %)              41 (21.2%)          15 (16.9%)          0.698     11 (15.9%)          15 (9.6%)            0.179
  Carperitide (yes, %)             109 (56.5%)         53 (59.6%)          0.426     32 (46.4%)          72 (45.9%)           1.000
  Dopamine (yes, %)                49 (25.4%)          17 (19.1%)          0.291     12 (17.4%)          37 (23.6%)           0.381
  Dobutamine (yes, %)              37 (19.2%)          16 (18.0%)          0.871     11 (15.9%)          26 (16.6%)           1.000
  ACE-I/ARB (yes, %)               64 (33.1%)          33 (37.1%)          0.590     27 (39.1%)          47 (29.9%)           0.218
  β-blocker (yes, %)               54 (28.0%)          24 (27.0%)          0.887     14 (20.3%)          25 (15.9%)           0.448
  Spironolactone (yes, %)          52 (26.9%)          30 (33.7%)          0.261     24 (34.8%)          46 (29.3%)           0.437
  Outcome                                                                                                                     
  ICU hospitalization (days)       4 (3-7)             4 (3-7)             0.810     5 (3-7)             4 (3-7)              0.553
  Total hospitalization (days)     26 (16-39)          23 (16-46)          0.768     35 (22-45)          28 (16-50)           0.025
  In-hospital mortality (yes, %)   11 (5.7%)           11 (12.4%)          0.059     8 (11.6%)           20 (12.7%)           1.000

LVEF: left ventricular ejection fraction measured by echocardiography, NYHA: New York Heart Association, BUN: blood urea nitrogen, CRP: C-reactive protein, BNP: brain natriuretic peptide, PNI: prognostic nutritional index, CONUT: controlling nutritional status, ACE-I: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, ICU: intensive-care unit

The p values between the non-socially vulnerable and socially vulnerable group were determined using the Mann-Whitney U-test or the χ^2^ test.

All numerical data are expressed as the median (25-75% interquartile range).

The prognosis
-------------

The median follow-up period was 546 (144-1,000) days. There were 104 (9.9%) in-hospital deaths, and 242 patients (23.1%) died within 1,000 days. The Kaplan-Meier curves for the socially vulnerable patients in each category are shown in [Figs. 2](#g002){ref-type="fig"} and [3](#g003){ref-type="fig"}.

![(A) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in men \<75 years of age. (B) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in women \<75 years of age.](1349-7235-58-2931-g002){#g002}

The rates of all-cause mortality were not significantly different between the socially vulnerable and non-socially vulnerable groups in non-elderly patients of either gender ([Fig. 2](#g002){ref-type="fig"}). Interestingly, the rate of all-cause mortality in the socially vulnerable group was significantly higher than in the non-socially vulnerable group in elderly men (p=0.010) but not in elderly women (p=0.344) ([Fig. 3](#g003){ref-type="fig"}). The univariate Cox regression analysis showed that a socially vulnerable status was a predictor of the 1,000-day mortality in the elderly male cohort \[HR: 1.868, 95% confidence interval (CI) 1.151-3.031, p=0.011\]; however, it was not a predictor in the elderly female cohort ([Table 3](#t003){ref-type="table"}). The multivariate Cox regression model revealed that a socially vulnerable status was an independent predictor of the 1,000-day mortality only in the elderly male cohort (HR: 1.942, 95% CI: 1.102-3.422, p=0.022) ([Table 3](#t003){ref-type="table"}). Furthermore, the rate of all-cause mortality in the socially vulnerable group was significantly higher than in the non-socially vulnerable group in elderly men with a reduced LVEF (p\<0.001) but not in elderly women with a reduced LVEF (p=0.428), elderly men with a preserved LVEF (p=0.176), and elderly women with a preserved LVEF (p=0.538) ([Fig. 4](#g004){ref-type="fig"}).

![(A) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was significantly poorer in the socially vulnerable group than in the non-socially vulnerable group in men ≥ 75 years of age (p=0.010). (B) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in women ≥ 75 years of age.](1349-7235-58-2931-g003){#g003}

###### 

The Univariate and Multivariate Analyses of the Associations between the Clinical Findings and 1,000-day All-cause Mortality.

                                             Univariate           Multivariate                                                     
  ------------------------------------------ ------------ ------- -------------- ------- --------- -- ------- ------- ---- ------- -------
  Socially vulnerable (yes)                  1.868        1.151   \-             3.031   0.011        1.942   1.102   \-   3.422   0.022
  Laboratory data                                                                                                                  
  Age (per 1-year increase)                  1.029        0.976   \-             1.085   0.288        0.980   0.918   \-   1.045   0.533
  SBP (≥140 mmHg)                            0.487        0.301   \-             0.788   0.003        0.505   0.290   \-   0.881   0.016
  eGFR (per 10-mL/min/1.73 m^2^ increase)    0.879        0.769   \-             1.004   0.058        0.977   0.843   \-   1.132   0.759
  Total bilirubin (per 1.0-mg/dL increase)   1.009        0.963   \-             1.057   0.715        1.045   0.986   \-   1.107   0.137
  Sodium (per 1.0-mmol/L increase)           0.960        0.914   \-             1.009   0.111        0.998   0.948   \-   1.051   0.951
  CRP (per 0.1-mg/dL increase)               1.001        0.986   \-             1.016   0.897        1.001   0.982   \-   1.020   0.950
  Hemoglobin (per 1.0-mg/dL increase)        0.836        0.758   \-             0.922   \<0.001      0.888   0.783   \-   1.006   0.063
  LVEF (per 10% increase)                    0.983        0.849   \-             1.139   0.824        1.000   0.840   \-   1.190   0.997
  BNP (per 10-pg/mL increase)                1.003        1.002   \-             1.005   \<0.001      1.002   1.001   \-   1.004   0.002

                                             Univariate           Multivariate                                                   
  ------------------------------------------ ------------ ------- -------------- ------- ------- -- ------- ------- ---- ------- -------
  Socially vulnerable (yes)                  1.281        0.767   \-             2.142   0.344      1.007   0.614   \-   1.889   0.795
  Laboratory data                                                                                                                
  Age (per 1-year increase)                  1.053        1.002   \-             1.107   0.040      1.043   0.983   \-   1.107   0.166
  SBP (≥140 mmHg)                            0.655        0.405   \-             1.059   0.085      0.640   0.369   \-   1.110   0.112
  eGFR (per 10-mL/min/1.73 m^2^ increase)    0.881        0.773                  1.004   0.057      0.846   0.724   \-   0.989   0.036
  Total bilirubin (per 1.0-mg/dL increase)   1.014        0.970   \-             1.061   0.531      0.997   0.939   \-   1.060   0.932
  Sodium (per 1.0-mmol/L increase)           0.932        0.884   \-             0.982   0.009      0.928   0.873   \-   0.987   0.017
  CRP (per 0.1-mg/dL increase)               1.005        0.947   \-             1.066   0.882      0.927   0.844   \-   1.018   0.113
  Hemoglobin (per 1.0-mg/dL increase)        1.043        0.920   \-             1.181   0.511      1.150   0.981   \-   1.348   0.086
  LVEF (per 10% increase)                    0.920        0.794   \-             1.066   0.267      0.970   0.821   \-   1.147   0.724
  BNP (per 10-pg/mL increase)                1.002        1.000   \-             1.004   0.046      1.002   1.000   \-   1.004   0.111

HR: hazard ratio, CI: confidence interval, SBP: systolic blood pressure, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein, LVEF: left ventricular ejection fraction measured by echocardiography, BNP: brain natriuretic peptide

![(A) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was significantly poorer in the socially vulnerable group than in the non-socially vulnerable group in men ≥ 75 years of age and reduced LVEF (p\<0.001). (B) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in women ≥ 75 years of age. and reduced LVEF (p=0.428). (C) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in men ≥ 75 years of age and preserved LVEF (p=0.176). (D) The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was not significantly different between the socially vulnerable group and the non-socially vulnerable group in women ≥ 75 years of age and preserved LVEF (p=0.176). HFrEF: haert failure reduced ejection fraction, HFpEF: heart failure preserved ejection faraction, LVEF: left ventricular ejection fraction](1349-7235-58-2931-g004){#g004}

Discussion
==========

The present study showed that the proportion of socially vulnerable patients was higher in elderly female AHF patients than in elderly male AHF patients. However, social vulnerability was only associated with a poor prognosis in the elderly male AHF cohort.

We previously reported that socially vulnerability is correlated with a poor outcome of AHF. In addition, we showed in the present study that the socially poor AHF cohort included a large number of elderly women. Since the life expectancy of women is longer than that of men in Japan, elderly women tend to lose their partners and consequently become socially vulnerable. We also reported that being an elderly woman is independently associated with a worse mortality in patients with AHF ([@B9]). From this perspective, we hypothesized that the major reason for the poor prognosis in socially vulnerable elderly patients with AHF may be due to the fact that many such patients tend to be widowed women, which means that social vulnerability may thus be more strongly associated with a poor prognosis in the elderly female cohort than in the elderly male cohort.

Contrary to our expectations, however, the present study showed that social vulnerability was not associated with a poor prognosis in the elderly female cohort but was associated with such an outcome in the elderly male cohort. This result indicates that female patients can maintain control of their environment even if they become socially poor (having no partner or children or living alone) in their elderly years. In contrast, male patients may not be able to manage as well when they become socially poor.

Definition of socially vulnerable HF patients
---------------------------------------------

The present study defined social vulnerability as not having a partner (including patients who had never married or were divorced or widowed), not having any children, or living alone, as in our previous report ([@B6]). Previous studies have considered household incomes, health insurance, occupation, and educational background as components of being socially poor ([@B14],[@B15]). However, the Japanese medical service system basically covers all people, regardless of their income, medical insurance type, occupation, or educational background. We therefore did not regard these factors as important social factors. In addition, social isolation (being unmarried, divorced, or widowed; not having children; or living alone) is an independent risk factor of cardiovascular disease (CVD), as a previous study has already shown ([@B16]). We therefore conclusively defined socially vulnerable HF according to the existence of partners or family members in the present study.

The prognosis of HF in socially vulnerable patients
---------------------------------------------------

Several explanations have been proposed for the association between social determinants and patient outcomes. Previous studies have shown that chronic HF patients with symptoms of depression caused by psychological stress or minor depression were at a higher risk of poor self-care than those without symptoms of depression ([@B17]). The symptoms of depression might be exacerbated after admission in AHF patients and might be further exacerbated in socially vulnerable patients. Second, the lack of medical supervision is also a major problem for these patients. Medication adherence is reported to be involved in the relationship between marital status and the event-free survival in patients with HF ([@B18]). Patients with a better socioeconomic status might therefore be more likely to keep taking their prescribed medications. This might be the strongest predictor of a better outcome in connection with the socioeconomic status. Third, chronic HF is sometimes complicated by malnutrition, which can lead to muscle weakness, cognitive impairment and dysphagia; thus, the nutrition status (i.e. extremely low body mass index) is also reported to be a predictor of an adverse outcome in patients with AHF ([@B19],[@B20]). Living alone is suggested to be associated with a poor-quality diet and poor dietary patterns ([@B21]). Finally, these patients would have found it more difficult to visit a hospital immediately after the manifestation of symptoms than those with a partner or children.

The prognosis of socially poor HF patients according to gender differences
--------------------------------------------------------------------------

Among patients with coronary artery disease, male patients who are divorced or widowed show a poorer prognosis than married male patients ([@B22],[@B23]). Furthermore, according to the Cancer Prevention Study-II report, among Caucasians, the HR for the all-cause mortality was higher in non-married men than in non-married women ([@B24]). However, there have been some reports showing that women are more sensitive and vulnerable to psychosocial stress, financial stress, or social isolation than men, which might affect the progression of HF and CVD ([@B25]-[@B27]). Thus, whether or not gender difference affects the prognosis of socially poor patients with cardiovascular heart disease remains controversial.

However, there have been no reports describing the prognosis of socially poor HF according to gender differences. The present study regarding AHF showed that only elderly male socially vulnerable patients suffered an adverse outcome. While the mechanism underlying this effect has not yet been clarified, several studies have explored the mechanism involved in the mortality discrepancy between genders in socially vulnerable patients with CVD ([@B11],[@B23],[@B28]). Women historically manage the household and assume a nurturing role, potentially imbuing them with better self-care skills than their male counterparts. In addition, women socialize differently than men and may have stronger social networks outside of their homes than men. This may lead to a better outreach situation for female CVD patients, who would then demonstrate better attendance to physician appointments or cardiac rehabilitation. Furthermore, psychological stress, medication adherence and nutrition status may also be responsible for the gender differences in the prognosis of socially vulnerable HF ([@B17],[@B18],[@B21]). Women can therefore maintain control of their life environment even if they become socially poor (having no partner or children or living alone) in later life. Further investigations will be required to clearly elucidate the mechanisms underlying this gender-based difference by examining each factor potentially associated with socially poor HF by gender.

A multifactorial program involving physicians and social workers (i.e. home health services and home healthcare provided by visiting doctors, nurses, social workers, and physicians) as well as other options, such as discharge to institutions like nursing homes, elderly care facilities that provide intensive care, and group homes, may be necessary to avoid repeated admission for elderly male AHF patients. Such efforts might help reduce the rates of morbidity and mortality of socially vulnerable elderly male AHF patients. Nursing homes in particular may provide better care to elderly patients with poor social support than to non-elderly patients. In addition, frequent outpatient clinic visits may also help prevent social isolation among elderly men. Based on the results of the present study, we should consider implementing new management practices to prevent repeated admissions and eventually reduce the rate of mortality for elderly socially vulnerable male AHF patients.

Study limitations
-----------------

The present study is associated with several limitations. First, this was a retrospective study that was performed at a single center. It is therefore possible that unmeasured variables or missing data affected the results. Second, our study population was limited to patients who were admitted to the ICU; thus, AHF patients who were admitted to the general ward were excluded from this study. The patients were treated in a "closed ICU" at our institute. All of the physicians in our "closed ICU" are cardiologists. Thus, the majority of patients with severely decompensated AHF were admitted to the ICU. Third, the present study defined social vulnerability based on the marriage status (widowed, divorced, or unmarried), offspring status (no children), and living status (living alone). It is unclear whether this definition can be used to accurately select socially vulnerable patients. The results might have differed if other social determinants (i.e. the level of education or household income) had been used. In addition, patients living in a nursing home were considered to be socially vulnerable in the present study, as they were classified as "living alone". It is difficult to judge whether or not such patients are actually socially vulnerable. As a reference, however, Lu et al. reported that nursing home patients showed a poor prognosis ([@B5]). Finally, the present study was a retrospective one, and the data were only collected from medical records. While we can obtain accurate data on "single status" at the time of admission from medical records, it can be difficult to judge the details clearly (widowed, divorced, or unmarried). The status of divorced or widowed was not clear based on the medical records; furthermore, there might have been some interaction between divorced and widowed status. This may be a major limitation associated with the present study. Further prospective studies will be required to evaluate this issue.

Conclusion
==========

Social vulnerability was more common in elderly AHF patients, especially female AHF patients, than in non-elderly AHF patients. However, socially vulnerability was not associated with a poor prognosis in elderly female AHF patients; instead, such an association was only noted in elderly male AHF patients. Elderly women might manage their condition reasonably well even if they are socially vulnerable. Interventions to improve the social structure of socially vulnerable patients, especially elderly men, may help improve the prognosis of these patients in light of the oncoming AHF pandemic.
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